FDA clears Nurix Therapeutics, Inc.'s GS-6791 for inflammatory disorders; Nurix earns $5M milestone from Gilead. Click for my ...

Boehringer Ingelheim and Cue Biopharma have entered a strategic research partnership and licence agreement to develop and commercialise the latter’s CUE-501 product candidate for autoimmune conditions ...

We look forward to his continued partnership in his new role as a strategic advisor.” Dr. Banerjee added, "Artiva is leading ...

Pfizer and Flagship Pioneering have entered into an agreement aimed at discovering potential selective inhibitors for ...

One of the most promising aspects of AI and its integration into the pharmaceutical industry is the technology’s potential to ...

Pfizer (PFE) and Pioneering Medicines, Flagship Pioneering’s in-house drug discovery and development unit, announced an agreement to discover ...

Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth plank of their multibillion-dollar, 10-program partnership. The agreement will see Flagship’s in-house drug ...

"Autoimmune diseases impose a substantial ... "Through the power of our unique partnership model with Pfizer, we will leverage Logica to help address this gap with a promising novel approach ...